Research finds many oncology drugs have ‘little or no added benefit’
Hospital Pharmacy Europe
MARCH 7, 2024
Many oncology drugs approved by the European Medicines Agency (EMA) between 2005 and 2020 provide ‘little or no added benefit’ for patients, according to new research. Many drugs with higher benefit ratings were associated with more significant revenues for the associated pharmaceutical companies, they added.
Let's personalize your content